Jilin Jian Yisheng Pharmaceutical Co., Ltd. (002566.SZ)
- Previous Close
7.02 - Open
6.95 - Bid 7.07 x --
- Ask 7.08 x --
- Day's Range
7.01 - 7.10 - 52 Week Range
5.75 - 8.12 - Volume
4,469,200 - Avg. Volume
6,908,653 - Market Cap (intraday)
2.343B - Beta (5Y Monthly) --
- PE Ratio (TTM)
54.46 - EPS (TTM)
0.13 - Earnings Date --
- Forward Dividend & Yield 0.15 (2.14%)
- Ex-Dividend Date May 22, 2024
- 1y Target Est
--
Jilin Jian Yisheng Pharmaceutical Co., Ltd. manufactures and sells medicine, Chinese herbal medicine, cosmetics, and ginseng products in China. The company offers injections, tablets, granules, hard capsules, mixtures, eye drops, liniments, liquors, syrups, emulsions, and other raw materials. It also exports self-produced products and related technologies; imports raw and auxiliary materials, mechanical equipment, instruments, spare parts, and related technologies; and provides ordinary freight services. In addition, the company engages in the supplement business; packaging printing; development, processing, and sales of bee products; planting of Chinese herbal medicines; leasing of house, machinery, and equipment; sales of agricultural and sideline products; wholesale and retail of Chinese herbal, proprietary Chinese, decoction pieces of traditional Chinese, and western medicine; retail of medicines; and road transportation of dangerous goods. Further, the company manufactures and sells organic fertilizer and health supplies; health, prepackaged, and bulk food; and sells paper cutting products. Jilin Jian Yisheng Pharmaceutical Co., Ltd. was founded in 1997 and is based in Ji'an, China.
www.yisheng-pharm.comRecent News: 002566.SZ
View MorePerformance Overview: 002566.SZ
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002566.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002566.SZ
View MoreValuation Measures
Market Cap
2.32B
Enterprise Value
2.23B
Trailing P/E
54.12
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.70
Price/Book (mrq)
1.03
Enterprise Value/Revenue
3.56
Enterprise Value/EBITDA
35.37
Financial Highlights
Profitability and Income Statement
Profit Margin
6.84%
Return on Assets (ttm)
0.59%
Return on Equity (ttm)
1.76%
Revenue (ttm)
627.21M
Net Income Avi to Common (ttm)
42.93M
Diluted EPS (ttm)
0.13
Balance Sheet and Cash Flow
Total Cash (mrq)
578.6M
Total Debt/Equity (mrq)
20.77%
Levered Free Cash Flow (ttm)
-7.94M